Citius Pharmaceuticals (CTXR) Accounts Payables (2011 - 2026)

Citius Pharmaceuticals (CTXR) has reported Accounts Payables for 16 consecutive years, with $8.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 20.37% year-over-year to $8.0 million; the trailing twelve-month figure through Jun 2026 stood at $8.0 million (down 20.37% YoY), and the FY2025 full-year result was $13.7 million, up 177.92% from the prior year.
• Accounts Payables slipped to $8.0 million in Q2 2026 per CTXR's latest filing, from $9.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $13.7 million in Q3 2025 and bottomed at $1.2 million in Q3 2022.
• Historically, Accounts Payables has averaged $5.3 million across 5 years, with a median of $3.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 45.99% in 2024, then soared 506.86% in 2025.
• Over 5 years, Accounts Payables stood at $1.5 million in 2022, then jumped by 72.17% to $2.6 million in 2023, then surged by 178.18% to $7.4 million in 2024, then jumped by 49.66% to $11.0 million in 2025, then retreated by 27.07% to $8.0 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $8.0 million, $9.5 million, and $11.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.